Vimarsana
Biggest News Aggregation in the World

Page 3 - Lai Wang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lai Wang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lai Wang Today - Breaking & Trending Today

BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress - Vimarsana News

BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress

New follow-up results from Phase 3 SEQUOIA trial and post hoc safety analyses for BRUKINSA (zanubrutinib) reinforce potential across various B-cell malignancies Early results for BTK-targeted CDAC (BGB-16673)

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio - Vimarsana News

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

Highlights from early- and late-stage pipeline include -- combination data for cornerstone therapies BRUKINSA and tislelizumab -- early results for OX40 agonist BGB-A445 and BCL-2 inhibitor... | May 25, 2023

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio - Vimarsana News

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

Highlights from early- and late-stage pipeline include -- combination data for cornerstone therapies BRUKINSA and tislelizumab -- early results for OX40 agonist BGB-A445 and BCL-2 inhibitor BGB-11417 BeiGene

BeiGene Receives New Approvals for BRUKINSA (zanubrutinib) in China - Vimarsana News

BeiGene Receives New Approvals for BRUKINSA (zanubrutinib) in China

BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235),

BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China - Vimarsana News

BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China

BRUKINSA is approved for first-line treatment for CLL/SLL and WM in China and has multiple approved indications in more than 65 markets worldwide ... | May 6, 2023